Equities
Health CarePharmaceuticals & Biotechnology
  • Price (JPY)3,890.00
  • Today's Change25.00 / 0.65%
  • Shares traded771.20k
  • 1 Year change+35.73%
  • Beta0.6073
Data delayed at least 20 minutes, as of Jun 23 2021 07:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of pharmaceuticals and industrial raw materials mainly for amino acid and nucleic acid related substances, as well as healthcare products.

  • Revenue in JPY (TTM)322.17bn
  • Net income in JPY46.11bn
  • Incorporated1949
  • Employees5.42k
  • Location
    Kyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 352057200
  • Fax+81 352057182
  • Websitehttps://www.kyowakirin.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
JCR Pharmaceuticals Co Ltd30.09bn6.89bn460.39bn667.0063.9411.4352.4315.3055.5255.52242.37310.510.4950.69723.72--11.338.2916.8610.6874.0369.8522.9015.611.21--0.319526.4921.4011.52157.3630.9639.7118.13
Hisamitsu Pharmaceutical Co Inc114.51bn9.25bn481.18bn2.77k49.961.8335.614.20113.10113.101,400.123,086.820.37712.662.6041,339,350.003.115.943.546.7760.4162.178.2412.635.97--0.006339.53-18.78-6.69-50.52-12.25-8.030.8601
Medipal Holdings Corp3.21tn23.93bn534.29bn13.60k20.460.877211.040.1664106.81106.8114,384.402,490.981.9319.544.62--2.022.635.597.426.677.131.051.331.07--0.045725.34-1.291.18-36.98-4.91-16.418.45
Santen Pharmaceutical Co Ltd249.61bn6.83bn620.97bn4.11k91.312.0226.522.4916.9916.99623.70769.310.61552.562.73--1.646.092.007.3260.6561.262.6610.212.1025.890.099444.813.335.03-71.10-33.7221.232.29
Nippon Shinyaku Co., Ltd.121.89bn20.70bn643.50bn2.03k29.803.8026.515.28307.37307.371,809.642,409.010.65521.533.00--11.149.6313.1611.4159.0255.5817.0014.213.29----30.434.507.6822.7426.704.9328.73
Peptidream Inc12.74bn5.23bn717.66bn128.00138.2532.36123.6556.3239.9339.9398.29170.580.60654.5533.2899,550,960.0024.87--26.87--81.86--41.01--6.15--0.00--------------
Sumitomo Dainippon Pharma Co Ltd515.95bn56.22bn893.68bn6.46k15.871.5415.021.73141.50141.501,298.671,461.310.40241.613.82--2.874.404.556.4773.3074.837.148.841.32--0.29720.706.885.0537.9517.882.109.24
ONO PHARMACEUTICAL CO., LTD.309.28bn75.43bn1.33tn3.61k16.631.9714.544.29151.09151.09619.531,273.280.43552.383.8485,745,500.0010.639.1812.3410.5872.3372.8424.4121.012.22--0.013939.255.7714.0526.3324.737.586.79
Kyowa Kirin Co Ltd322.17bn46.11bn2.09tn5.42k45.062.9331.376.4885.7885.78599.421,317.630.40731.573.5059,408,820.005.835.636.496.3574.1168.9514.3112.984.90--0.024845.264.10-2.6624.839.5711.8811.97
Eisai Co., Ltd645.94bn42.12bn3.77tn11.24k86.525.1847.845.84146.91146.912,253.062,452.970.60032.143.9557,483,490.003.956.265.338.3675.0370.876.5810.501.69--0.109969.26-7.143.35-65.41-5.17-0.98131.30
Daiichi Sankyo Co Ltd962.52bn75.96bn4.93tn16.03k64.873.8136.995.1239.0139.01495.64663.850.45941.813.5660,033,370.003.624.034.354.9064.8563.647.888.413.02--0.15157.46-1.96-0.49-41.34-1.63-1.586.19
Data as of Jun 23 2021. Currency figures normalised to Kyowa Kirin Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

12.20%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 31 May 202118.97m3.51%
Nikko Asset Management Co., Ltd.as of 04 Jun 20218.49m1.57%
Daiwa Asset Management Co. Ltd.as of 31 May 20218.15m1.51%
Massachusetts Financial Services Co.as of 31 Mar 20217.58m1.40%
The Vanguard Group, Inc.as of 31 May 20216.24m1.16%
BlackRock Fund Advisorsas of 03 Jun 20214.58m0.85%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 03 Jun 20214.24m0.79%
Norges Bank Investment Managementas of 31 Dec 20203.95m0.73%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 18 Jun 20211.97m0.37%
T. Rowe Price International Ltd. (Japan)as of 31 Mar 20211.70m0.31%
More ▼
Data from 31 Dec 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.